Prevalence and risk factors for extended spectrum Beta-lactamase-producing uropathogens in patients with urinary tract infection
- PMID: 20664784
- PMCID: PMC2907500
- DOI: 10.4111/kju.2010.51.7.492
Prevalence and risk factors for extended spectrum Beta-lactamase-producing uropathogens in patients with urinary tract infection
Abstract
Purpose: The aim of this study was to determine the prevalence and risk factors of extended spectrum beta-lactamase (ESBL)-producing microorganisms in urinary tract infection.
Materials and methods: total of 2,312 patients older than 25 years and diagnosed from January 2007 to December 2009 as having urinary tract infection were studied. The prevalence of ESBL-producing microorganisms including Escherichia coli and the antimicrobial susceptibility of E. coli were examined. Univariate analyses were performed with gender, age, inpatient status, previous hospitalization, recent history of urinary catheterization, recent exposure to specific antibiotics, and past history of urogenital organ operation as risk factors for the emergence of ESBL-producing microorganisms. Then, multivariate analysis was performed with all significant variables.
Results: In outpatient urinary tract infection, the antimicrobial susceptibility of E. coli to each of the third-generation cephalosporins, cefotaxime, ceftazidime, and ceftriaxone, was 87.6%, 93.4%, and 87.7%, respectively, and the prevalence of ESBL-producing E. coli was 12.1%. In inpatient urinary tract infection, the susceptibility of E. coli was 78%, 84.5%, and 76.9%, respectively, and the prevalence was 23.1%.
Conclusions: The overall prevalence of ESBL-producing microorganism was 12.6% and the risk appeared to be increased in cases with a previous hospitalization, a recent history of urinary catheterization, inpatient status, cefaclor medication, cefminox administration, and female gender.
Keywords: Beta-lactamases; Cephalosporins; Prevalence; Risk factors.
Conflict of interest statement
The authors have nothing to disclose.
References
-
- Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE Infectious Diseases Society of America (IDSA) Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis. 1999;29:745–758. - PubMed
-
- Colodner R, Kometiani I, Chazan B, Raz R. Risk factors for community-acquired urinary tract infection due to quinolone-resistant E. coli. Infection. 2008;36:41–45. - PubMed
-
- National Institute of Public Health and the Environment. European Antimicrobial Resistance Surveillance System (EARSS) annual report 2008. Bilthoven: The Institue; 2009.
-
- Karlowsky JA, Jones ME, Thornsberry C, Critchley I, Kelly LJ, Sahm DF. Prevalence of antimicrobial resistance among urinary tract pathogens isolated from female outpatients across the US in 1999. Int J Antimicrob Agents. 2001;18:121–127. - PubMed
-
- Zhanel GG, Hisanaga TL, Laing NM, DeCorby MR, Nichol KA, Palatnik LP, et al. Antibiotic resistance in outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA) Int J Antimicrob Agents. 2005;26:380–388. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous
